Each week, Weight & Measure highlights studies worth your attention, explains their findings, and puts their limits into plain language.
What happens to lean mass on tirzepatide and semaglutide?
A study published November 12 in npj Exercise Medicine and Health found that people taking tirzepatide had a 2.1 percentage point greater decline in lean mass at 12 months than people taking semaglutide. But once researchers accounted for how much total weight people lost, that difference narrowed to 0.1 percentage points and was statistically uncertain. Lean mass accounted for roughly one-fifth of the weight lost with either medication. This is a useful follow-up to a question we’ve asked on Weight & Measure: Is weight loss enough? The scale tells us how much weight changed. Strength, physical function, and body composition can help us understand what that change means for someone’s daily life.
This was an observational study, and only about 1.2% of people starting either medication had body composition measurements before and after treatment. Most measurements came from bioelectrical impedance, which can be influenced by hydration. And lean mass includes more than skeletal muscle, so the study cannot tell us how much muscle people lost or whether one medication preserves muscle better than the other.
Worth reading: Original peer-reviewed study ↗ · Related Weight & Measure guide →
Could genetics help explain why people respond differently to obesity medications?
A brief report published November 11 in Nature Metabolism examined rare variants in GLP1R, the gene that encodes the GLP-1 receptor. People with these variants lost less weight on semaglutide than matched people without them. Researchers did not detect the same pattern with tirzepatide. If you’ve ever wondered why two people can take the same obesity management medication (OMM) and have very different experiences, this study offers one possible piece of the answer. It also gives us a better starting point for talking about treatment response without making assumptions about someone’s effort.
The study was retrospective, and few people carried the variants. The findings do not tell us whether genetic testing would help someone choose a medication or whether switching medications would improve their response. Those questions need to be tested directly.
Worth reading: Original peer-reviewed study ↗ · Related Weight & Measure guide →
What 517 GLP-1 trials tell us about the questions we still need to ask
A systematic evidence map published November 9 in Obesity Surgery cataloged 517 randomized trials of GLP-1–based therapies over two decades, through June 2025. It shows how the field expanded from blood sugar management to weight management and outcomes involving the heart and kidneys. As OMMs become part of more conversations about metabolic & bariatric surgery, the map is a useful starting point for asking where research can inform decisions and where more direct comparisons are needed.
The authors mapped what researchers studied without pooling the results for benefits or harms. So even with 517 trials, this paper cannot answer a practical question many patients face: When might it make sense to start a medication before or after surgery? The trial count tells us how much research has been done across the field. To answer a question about timing, we still need studies designed around that decision.
Worth reading: Original peer-reviewed study ↗ · Related Weight & Measure guide →
What we're watching
Heading into ObesityWeek, one question is on our minds: What should we measure to know whether obesity treatment is helping someone? Weight change is one part of that conversation. We’re also looking for research that tells us how people feel and function during treatment, why responses differ, and what evidence can help patients and practitioners decide what comes next. More science. Less stigma.
Weight & Measure translates obesity science for the people living it. Educational information only, not personal medical advice.
More science. Less stigma.